These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 23504603

  • 1. Immunotherapy and endothelin receptor antagonists for treatment of castration-resistant prostate cancer.
    Shao N, Wang Y, Jiang WY, Qiao D, Zhang SG, Wu Y, Zhang XX, Wang JL, Ding Y, Feng NH.
    Int J Cancer; 2013 Oct 01; 133(7):1743-50. PubMed ID: 23504603
    [Abstract] [Full Text] [Related]

  • 2. The efficacy and safety of zibotentan in the treatment of castration-resistant prostate cancer: a meta-analysis.
    Wu Y, Shao N, Shen ZX, Li Q, Wang Y, Li C, Ma G, Dong J, Lu XJ, Feng NH.
    Eur Rev Med Pharmacol Sci; 2014 Oct 01; 18(21):3291-6. PubMed ID: 25487941
    [Abstract] [Full Text] [Related]

  • 3. A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer.
    Qi P, Chen M, Zhang LX, Song RX, He ZH, Wang ZP.
    PLoS One; 2015 Oct 01; 10(7):e0133803. PubMed ID: 26192308
    [Abstract] [Full Text] [Related]

  • 4. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone.
    Nelson JB, Fizazi K, Miller K, Higano C, Moul JW, Akaza H, Morris T, McIntosh S, Pemberton K, Gleave M.
    Cancer; 2012 Nov 15; 118(22):5709-18. PubMed ID: 22786751
    [Abstract] [Full Text] [Related]

  • 5. Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer.
    Miller K, Moul JW, Gleave M, Fizazi K, Nelson JB, Morris T, Nathan FE, McIntosh S, Pemberton K, Higano CS.
    Prostate Cancer Prostatic Dis; 2013 Jun 15; 16(2):187-92. PubMed ID: 23381694
    [Abstract] [Full Text] [Related]

  • 6. ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer.
    Warren R, Liu G.
    Expert Opin Investig Drugs; 2008 Aug 15; 17(8):1237-45. PubMed ID: 18616419
    [Abstract] [Full Text] [Related]

  • 7. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.
    Fizazi K, Higano CS, Nelson JB, Gleave M, Miller K, Morris T, Nathan FE, McIntosh S, Pemberton K, Moul JW.
    J Clin Oncol; 2013 May 10; 31(14):1740-7. PubMed ID: 23569308
    [Abstract] [Full Text] [Related]

  • 8. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial.
    James ND, Caty A, Payne H, Borre M, Zonnenberg BA, Beuzeboc P, McIntosh S, Morris T, Phung D, Dawson NA.
    BJU Int; 2010 Oct 10; 106(7):966-73. PubMed ID: 20840318
    [Abstract] [Full Text] [Related]

  • 9. [The treatment of castration-resistant prostate cancer].
    Petrányi Á.
    Magy Onkol; 2012 Dec 10; 56(4):219-28. PubMed ID: 23236591
    [Abstract] [Full Text] [Related]

  • 10. Current and emerging treatments in the management of castration-resistant prostate cancer.
    Shapiro D, Tareen B.
    Expert Rev Anticancer Ther; 2012 Jul 10; 12(7):951-64. PubMed ID: 22845410
    [Abstract] [Full Text] [Related]

  • 11. New therapies for castration-resistant prostate cancer: efficacy and safety.
    Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF.
    Eur Urol; 2011 Aug 10; 60(2):279-90. PubMed ID: 21592649
    [Abstract] [Full Text] [Related]

  • 12. Novel options for the treatment of castration-resistant prostate cancer.
    Ohlmann CH, Merseburger AS, Suttmann H, Schilling D, Trojan L, Kempkensteffen C, Corvin S, Mathers MJ, Bastian PJ.
    World J Urol; 2012 Aug 10; 30(4):495-503. PubMed ID: 22101903
    [Abstract] [Full Text] [Related]

  • 13. Novel therapeutic approaches for the treatment of castration-resistant prostate cancer.
    Heidegger I, Massoner P, Eder IE, Pircher A, Pichler R, Aigner F, Bektic J, Horninger W, Klocker H.
    J Steroid Biochem Mol Biol; 2013 Nov 10; 138():248-56. PubMed ID: 23792785
    [Abstract] [Full Text] [Related]

  • 14. Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): a systematic review and meta-analysis.
    Botrel TE, Clark O, Pompeo AC, Bretas FF, Sadi MV, Ferreira U, Reis RB.
    Int Braz J Urol; 2012 Nov 10; 38(6):717-27. PubMed ID: 23302410
    [Abstract] [Full Text] [Related]

  • 15. [New drugs in metastatic castration-resistant prostate cancer].
    Albiges L, Loriot Y, Gross-Goupil M, de La Motte Rouge T, Blesius A, Escudier B, Massard C, Fizazi K.
    Bull Cancer; 2010 Jan 10; 97(1):149-59. PubMed ID: 20022854
    [Abstract] [Full Text] [Related]

  • 16. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
    Di Lorenzo G, Ferro M, Buonerba C.
    BJU Int; 2012 Jul 10; 110(2 Pt 2):E99-104. PubMed ID: 22177289
    [Abstract] [Full Text] [Related]

  • 17. Castration-resistant prostate cancer: AUA Guideline.
    Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, Penson DF, Kibel AS.
    J Urol; 2013 Aug 10; 190(2):429-38. PubMed ID: 23665272
    [Abstract] [Full Text] [Related]

  • 18. [Immunotherapy: an emerging strategies against prostate castration resistant cancer].
    Mansi L, Thiery-Vuillemin A, Kalbacher E, Nguyen T, Maurina T, Nallet J, Kim S, Borg C, Kleinclauss F, Pivot X, Adotevi O.
    Bull Cancer; 2012 Jul 10; 99 Suppl 1():S57-65. PubMed ID: 22516539
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA.
    Eur Urol; 2009 May 10; 55(5):1112-23. PubMed ID: 19042080
    [Abstract] [Full Text] [Related]

  • 20. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens.
    Caubet JF, Tosteson TD, Dong EW, Naylon EM, Whiting GW, Ernstoff MS, Ross SD.
    Urology; 1997 Jan 10; 49(1):71-8. PubMed ID: 9000189
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.